Previous 10 |
NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate over...
Rain Therapeutics shares rise ([[RAIN]] +13.9%) after the company posted first-quarter results and provided a cash position update.The company expects the full year 2021 net cash used in operating and investing activities to be about $50M to $60M and a projected year end cash balanc...
Rain Therapeutics (RAIN): Q1 GAAP EPS of -$1.93 misses by $0.23.As of March 31, 2021, Rain had $53.1M in cash and cash equivalents which does not include the net proceeds from the IPO in April 2021 of $121.9M.The Company expects the full year 2021 net cash used i...
Completed initial public offering ("IPO") with net proceeds of $121.9 million Key appointments to the leadership team, board of directors and scientific advisory board Planned Phase 3 trial initiation in 2H 2021 for RAIN-32 in well-differentiated ("WD")/de-differentiated (...
NEWARK, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the appointment of Rain co-founder Robert Doebele, M.D., Ph.D. as president and chief scientific officer ...
Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI) +8%.Express (EXPR) +7%.Eloxx Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Rain Therapeutics Inc. Company Name:
RAIN Stock Symbol:
NASDAQ Market:
Rain Therapeutics Inc. Website:
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire ...
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable conting...